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To evaluate the long-term consequences of acute kidney
injury (AKI) in human immunodeficiency virus (HIV)-infected
persons, we studied 17,325 patients in a national HIV registry
during their first hospitalization. We determined the
association of AKI with risk for heart failure, cardiovascular
events, end-stage renal disease (ESRD), and mortality
beginning 90 days after discharge. Based on AKI Network
criteria, 2453 had stage 1; 273 had stage 2 or 3; and 334 had
dialysis-requiring AKI. Over a mean follow-up period of 5.7
years, 333 had heart failure, 673 had cardiovascular diseases
(CVDs), 348 developed ESRD, and 8405 deaths occurred. In
multivariable-adjusted analyses, AKI stage 1 was associated
with death and ESRD, but not heart failure or other CVD.
Dialysis-requiring AKI had much stronger and significant
associations with increased risk for long-term ESRD, and
death in addition to heart failure and cardiovascular events.
When AKI was reclassified to account for recovery, stage 1
with recovery was still associated with death, but not ESRD.
Thus, in this national sample of HIV-infected persons, we
found the clinical repercussions of AKI appear to extend
beyond the hospital setting contributing to excess
cardiovascular risks, ESRD, and mortality. Additionally, AKI
affected almost one of six patients with HIV who survived at
least 90 days following discharge.
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Acute kidney injury (AKI), also known as acute renal failure,
is commonly defined as a rapid decline in kidney function
marked by an increase in serum creatinine level. AKI is
increasingly recognized as an important management issue in
hospitalized patients, because it is relatively common,
affecting up to 7% of patients, and consistently associated
with high rates of in-hospital mortality.1,2 In addition, a
growing number of studies have linked AKI with long-term
outcomes after discharge, such as mortality and end-stage
renal disease (ESRD), even 10 years after the AKI has
occurred.3,4 These reports have stimulated a debate over the
mechanisms responsible for increased mortality in AKI, and
indicate a need to broaden investigation to other adverse
events that may be associated with AKI. For example,
although the majority of deaths in chronic kidney disease
(CKD) are thought to be related to cardiovascular disease
(CVD), a clear association has not been established between
AKI and incident heart failure or CVD.
Human immunodeficiency virus (HIV)-infected persons
are a population that may experience a high burden of
disease from AKI. Among hospitalized patients, AKI occurs
at 2–3 times the rate observed in uninfected controls.5
Furthermore, improved survival in the HIV-infected popula-
tion has shifted research priorities from effective treatment of
viral replication to understanding the importance of non-
AIDS-related chronic conditions and their risk factors. In the
contemporary era of antiretroviral therapy, CKD and CVD
have emerged as major causes of death in HIV-infected
persons.6,7 We previously found that kidney function and
albuminuria measured in the outpatient setting is associated
with adverse cardiovascular events in HIV-infected persons.8
Although, earlier studies have linked the natural history of
CKD with AKI, no studies have explored the potential
relationship between AKI, CVD, and mortality.9 To enhance
our understanding of the importance of AKI in HIV-infected
persons, we conducted an observational cohort study in a
national sample of 17,325 HIV-infected persons receiving
care in the Veterans Health Administration, and examined
the association between AKI experienced during their first
hospitalization with the development of heart failure,
atherosclerotic cardiovascular events, ESRD, and death over
a period of 2 decades.
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RESULTS
We identified 17,325 HIV-infected persons who survived at
least 90 days after discharge from their first hospitalization
over a 20-year period (Table 1). A large proportion of these
patients experienced AKI (18%) during their hospital stay.
Among those with AKI, stage 1 AKI (defined by a crude
serum creatinine increase of 0.3mg/dl or greater, or a relative
increase between 150 and 200%) was found in 80%
(n¼ 2453). Stage 2 or 3 AKI (marked by a relative creatinine
increase 4200%, or a crude increase of 0.5mg/dl in
individuals with a baseline creatinine of X4.0mg/dl) was
much less common (9%, n¼ 273). There were 334 patients
(11%) who experienced AKI treated with dialysis. Individuals
with AKI were more likely to be black, and have CKD
(estimated glomerular filtration rate (eGFR)o60ml/min per
1.73m2) or risk factors for CKD such as hypertension,
diabetes, low CD4 count, and elevated viral loads. Individuals
who were treated in the intensive care unit were also more
likely to experience AKI.
Over 98,208 person-years of follow-up (mean 5.7, s.d. 4.8
years), 333 heart failure events, 673 CVD events, 348 ESRD
events, and 8405 deaths occurred. The rates of heart failure,
CVD, ESRD, and mortality increased incrementally by stage
of AKI (Figure 1). Age-standardized rates of mortality were
far greater than those for heart failure, CVD, and ESRD. The
gradient in risk from no AKI to dialysis-requiring AKI was
steeper for heart failure (3 versus 16 per 1000 person-years),
than for CVD (9 versus 17 events per 1000 person-years), or
death (82 versus 188 events per 1000 person-years). However,
differences across AKI stages were particularly exaggerated
Table 1 | Baseline characteristics of 17,325 hospitalized HIV-infected persons, by stage of acute kidney injury (AKI)a
No AKI (n=14,265) AKI stage 1 (n=2453) AKI stage 2–3 (n=273) Dialysis-requiring AKI (n=334) P-value
Age 44 (9) 46 (10) 47 (9) 47 (10) o0.001
Race o0.001
White 28.0% 20.8% 12.8% 12.6%
Black 39.4% 40.0% 61.5% 52.4%
Other 32.6% 39.1% 25.6% 35.0%
Female 2.0% 1.4% 1.8% 0.9% 0.074
Comorbid conditions
Hypertension 18.9% 22.2% 31.9% 40.7% o0.001
Diabetes 6.8% 10.2% 11.0% 18.3% o0.001
Dyslipidemia 10.6% 10.7% 10.6% 16.5% 0.008
Liver disease 3.5% 3.5% 3.3% 6.6% 0.028
Lung disease 6.6% 5.9% 5.9% 6.0% 0.562
Smoking 17.2% 14.7% 15.0% 13.5% 0.007
Cancer 9.4% 11.9% 11.4% 14.4% o0.001
Heart failure 1.6% 3.6% 4.8% 8.7% o0.001
Cardiovascular disease 6.7% 7.1% 7.3% 11.1% 0.037
Hepatitis C virus infection 21.3% 20.6% 27.1% 19.5% 0.072
Hepatitis B virus infection 6.3% 6.9% 10.6% 9.6% 0.003
Baseline eGFR o0.001
X60ml/min per 1.73m2 93.8% 89.4% 66.3% 86.8%
30–59ml/min per 1.73m2 4.8% 8.5% 8.8% 2.7%
o30ml/min per 1.73m2 1.4% 2.1% 24.9% 10.5%
Albuminuria 29.7% 49.9% 67.8% 16.5% o0.001
HIV-related characteristics
Antiretroviral therapy 25.7% 24.9% 25.6% 21.3% 0.261
CD4 count, cells/mm3 267 (286) 181 (268) 195 (240) 200 (248) o0.001
Viral load, log copies 3.5 (1.5) 3.9 (1.5) 3.9 (1.4) 3.5 (1.7) o0.001
Intensive care unit stay 5.7% 12.6% 24.2% 28.4% o0.001
Hospitalization after 1995 49.0% 52.6% 63.7% 52.1% o0.001
aReported as proportion with condition (%); continuous variables reported as mean (s.d.). eGFR, estimated glomerular filtration rate; albuminuria defined as X30mg/dl on
dipstick urinalysis.
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Figure 1 |Age-standardized event rates 90 days after
discharge by stage of in-hospital acute kidney injury. Note
that y axis is on log2 scale.
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for ESRD; ESRD was nearly 16 times as common in those
with dialysis-requiring AKI compared with those without
AKI (56 versus 4 events per 1000 person-years).
In Cox proportional hazards regression models (Table 2)
adjusted for characteristics in Table 1, adjusted hazard ratios
for stage of AKI increased incrementally. Associations were
strongest for ESRD, where a 37% increased risk for long-term
chronic dialysis therapy was observed in those with the
mildest form of AKI. Despite multivariable adjustment for
demographic factors, baseline kidney function and albumi-
nuria, HIV-related factors, and comorbid conditions, all
stages of AKI remained associated with an increased risk for
mortality. The association between AKI and the outcomes of
heart failure and CVD changed minimally when results were
stratified by those with or without a history of these
conditions. We also did not detect significant interactions
between AKI and calendar year (i.e., antiretroviral treatment
era). In subgroup analyses for mortality (Figure 2), AKI was
consistently associated with harm; however, hazard ratios
were smaller in magnitude among those with greater severity
of disease at baseline marked by lower CD4 count, detectable
viral load, prevalent kidney disease, or hospitalization in the
intensive care unit. Also, to better characterize the effect of
baseline eGFRo60ml/min per 1.73m2 and albuminuria, we
divided the cohort into four mutually exclusive categories
defined by (1) the absence of these conditions, (2) albuminuria
only, (3) eGFRo60ml/min per 1.73m2 only, and (4) both
conditions. Results were consistent with the primary subgroup
analysis (Figure 2), with the adjusted risk of mortality associated
with AKI: 1.41 (1.31–1.52), 1.16 (1.06–1.28), 1.02 (0.73–1.43),
and 1.06 (0.86–1.31) in respective categories. Similar patterns
Table 2 | The association between in-hospital acute kidney injury (AKI) with long-term adverse eventsa
No AKI (n=14,265) AKI stage 1 (n=2453) AKI stage 2–3 (n=273) Dialysis-requiring AKI (n=334) P-value for trend
Heart failure
Number of events 250 53 14 16
Demographic adjusted 1.0 1.39 (0.98–1.95) 3.28 (1.73–6.22) 4.57 (2.53–8.28) o0.001
Multivariable adjusted 1.0 1.17 (0.82–1.67) 2.11 (1.07–4.16) 4.20 (2.24–7.88) o0.001
CVD
Number of events 559 85 14 15
Demographic adjusted 1.0 1.01 (0.80–1.27) 1.71 (1.00–2.91) 1.85 (1.10–3.10) 0.120
Multivariable adjusted 1.0 0.98 (0.77–1.24) 1.34 (0.77–2.35) 1.96 (1.14–3.38) 0.051
End-stage renal disease
Number of events 230 63 23 32
Demographic adjusted 1.0 2.03 (1.54–2.69) 9.09 (5.89–14.02) 23.54 (16.09–34.44) o0.001
Multivariable adjusted 1.0 1.37 (1.02–1.84) 3.80 (2.32–6.23) 20.36 (12.65–32.78) o0.001
Death
Number of events 6681 1377 150 197
Demographic adjusted 1.0 1.31 (1.23–1.38) 1.53 (1.30–1.80) 1.69 (1.46–1.94) o0.001
Multivariable adjusted 1.0 1.20 (1.13–1.28) 1.18 (1.00–1.41) 1.73 (1.49–2.01) o0.001
aAdjusted estimates reported as hazard ratio (95% confidence interval). Demographic adjusted models control for age, sex, and race. All factors in Table 1 were candidate
variables for fully adjusted models.
Multivariable models for cardiovascular disease and heart failure include: age, sex, race, baseline estimated glomerular filtration rate, albuminuria, CD4 count, hypertension,
diabetes, history of heart failure, history of cardiovascular disease (CVD), hospitalization in the intensive care unit, and calendar year.
Multivariable models for end-stage renal disease include: age and age square, sex, race, baseline estimated glomerular filtration rate, albuminuria, CD4 count, hypertension,
diabetes, hospitalization in the intensive care unit, and calendar year.
Multivariable adjusted models for death include: age, sex, race, baseline estimated glomerular filtration rate, albuminuria, viral load, CD4 count, hypertension, diabetes, lung
disease, smoking, cancer, history of CVD, hospitalization in the intensive care unit, and calendar year.
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Figure 2 |Association of acute kidney injury with mortality
within subgroups defined by baseline characteristics. Stages
of acute kidney injury combined into a dichotomous variable (no
AKI versus AKI) to allow adequate statistical power to analyze
subgroups. CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate; ICU, intensive care unit. Units for
variables: age (years), eGFR (ml/min per 1.73m2), CD4 count (cells/
mm3). All estimates adjusted for factors as described in Table 2.
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were observed in the subgroup analysis for ESRD (Figure 3);
however, the magnitude of associations between AKI and ESRD
were stronger than for death.
For the primary analysis, creatinine changes were defined
by increases from the most recent outpatient creatinine
measure before hospitalization. However, in 13% of the study
sample, in whom pre-hospitalization outpatient creatinine
measurements were not available, the first in-patient
creatinine level was used as the baseline measure of kidney
function. In sensitivity analyses, we tested alternative
definitions of AKI using the nadir in-patient creatinine to
define baseline kidney function and also by applying a 48-h
time criterion for creatinine increase. For both of these
analyses, results changed minimally from the primary
findings (data not shown). In addition, when using the
CKD-EPI equation to define eGFR instead of the Modifica-
tion of Diet in Renal Disease formula, we found that results
did not change.
Next, we examined the risk for each outcome after refining
the classification for AKI to account for recovery status at the
time of discharge from the hospital (Table 3). In contrast to
patients without recovery from AKI stage 1, those who
recovered had no increased risk for ESRD. Nonetheless,
patients with stage 1 AKI with recovery had a 20% higher risk
of mortality, compared with those who did not experience
AKI. The risk for ESRD was altered most dramatically when
AKI was reclassified by recovery status. Those with AKI stages
2–3 with recovery had a twofold risk for ESRD, in contrast to
the 10-fold increase in risk observed among those with AKI
stages 2–3 without recovery.
DISCUSSION
In this large cohort of 17,325 hospitalized HIV-infected
veterans receiving care in a relatively uniform health
system, AKI was a common occurrence, affecting one of
six patients who survived at least 90 days after discharge.
We observed graded, independent associations between
severity of AKI with heart failure, CVD, ESRD, and death.
Our study is the first to report an association between
AKI and the incidence of heart failure and CVD, while
confirming previously established associations with ESRD
and death. Furthermore, we refined the prognostic value
of these associations by examining the effect of recovery
from AKI. We found that AKI stage I was not associated
with heart failure, CVD, or ESRD in those who recovered
kidney function, yet surprisingly maintained an association
with death. In subgroup analyses, the association between
AKI with mortality and ESRD appeared to be stronger
in those without prevalent CKD, and reduced GFR in
particular. Finally, our study extends the epidemiology of
AKI to an understudied population, HIV-infected persons,
in whom the long-term consequences of AKI have never
been reported.
Previous reports of AKI in HIV-infected persons
Earlier studies have found that AKI is associated with an
increased risk of mortality in HIV-infected persons in the era
of antiretroviral therapy. A study of adult hospitalized
patients in New York State found AKI, ascertained by
diagnostic codes, occurred in 6% of HIV-infected indivi-
duals, and was associated with an approximate fivefold
increase in in-hospital mortality.5 Lopes et al.10 used the
Risk, Injury, Failure, Loss, and End Stage Kidney Disease
(RIFLE) criteria to classify AKI in 97 critically ill HIV-infected
patients in Portugal. These authors found that 47% of the
patients studied had AKI, and there was a graded risk of 60-day
mortality based on RIFLE staging.10 No studies have evaluated
the association of AKI with long-term survival or other adverse
events in HIV-infected persons.
Earlier studies of cardiovascular events after AKI
In the general population without HIV, a number of recent
studies have examined long-term clinical outcomes.3,4,9,11,12
Although the majority of studies have identified associations
between AKI with ESRD and death, few have investigated
intermediary outcomes such as cardiovascular events. All
of these studies have been conducted in persons either
receiving percutaneous coronary intervention or admitted
for myocardial infarction.12–14 Goldberg et al.14 also addressed
the issue of recovery from AKI in a study of 1957 patients
who survived acute myocardial infarction; they also found
that recovery from AKI mitigated the risk for heart failure
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Figure 3 |Association of acute kidney injury with ESRD within
subgroups defined by baseline characteristics. Stages of acute
kidney injury combined into a dichotomous variable (no AKI
versus AKI) to allow adequate statistical power to analyze
subgroups. CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate; ICU, intensive care unit. Units for
variables: age (years), eGFR (ml/min per 1.73m2), CD4 count (cells/
mm3). All estimates adjusted for factors as described in Table 2.
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and CVD associated with AKI. We confirm these associations
in HIV-infected patients unselected for prevalent CVD, and
demonstrate a dose-dependent relationship between AKI and
risk of adverse cardiovascular events.
Mechanisms
Our study results indicate that the clinical repercussions
of AKI appear to extend beyond the hospital setting, and
may contribute to adverse outcomes years after the AKI
has occurred. These findings raise the possibility that AKI
may be an inciting event that triggers a cascade of
perturbations that never completely resolve. In animal
models of AKI, permanent alterations in tubular, glomerular,
and vascular structure such as atrophy and dilatation and loss
of function are evident 40 weeks after injury.15–18 Impor-
tantly, AKI also triggers endothelial dysfunction, hypercoa-
gulability, and upregulation of cytokines, such as interleukin-1,
interleukin-6, tumor necrosis factor-a, which lead to distant
organ injury and dysfunction in the heart, lungs, and
brain.19–23 In these organs, it is possible that the long-term
effects may be due to a loss of functional reserve that is only
manifest in later years by a reduced ability to withstand an
acute physiologic stressor event.
Similar processes have been described as a result of HIV
infection. HIV triggers a systemic inflammatory response
that leads to chronic immune activation and a prothrom-
botic state, which also features increases in interleukin-1,
interleukin-6, and tumor necrosis factor-a.24–26 These
abnormalities have been implicated in the pathogenesis of
atherosclerosis, progression to AIDS, and mortality in HIV-
infected persons;25–28 we speculate that AKI may magnify
these derangements through these common mechanisms.
Understanding the precise role of AKI in persistent immune
activation and inflammation may also provide insights into
both the pathogenesis of HIV and CKD.
Strengths and limitations
The strengths of this study include the broad scope of long-
term clinical outcomes examined, including heart failure,
CVD, ESRD, and mortality over a 20-year period, the
application of consensus recommendations to define AKI,
and the study population, which was a national sample of
patients, all of whom had accessed care in a relatively
uniform, low-cost health system. We also improve on the
limitations of previous studies by using outpatient creatinine
measurements as the baseline level of kidney function and
Table 3 | The association between in-hospital acute kidney injury (AKI), recovery status, and adverse events 90 days after
dischargea
No AKI
(n=14,265)
AKI stage 1 with
recovery (n=1487)
AKI stage 1 without
recovery (n=966)
AKI stage 2–3 with
recovery (n=201)
AKI stage 2–3 without
recovery (n=72)
P-value for
trend
Heart failure
Number of
events
250 28 25 7 7
Demographic
adjusted
1.0 1.22 (0.78–1.92) 1.63 (1.02–2.62) 2.18 (0.90–5.31) 6.65 (2.73–16.23) o0.001
Multivariable
adjusted
1.0 1.00 (0.63–1.59) 1.45 (0.90–2.34) 1.90 (0.76–4.71) 2.38 (0.88–6.42) o0.001
Cardiovascular disease
Number of
events
559 54 31 9 5
Demographic
adjusted
1.0 1.05 (0.79–1.39) 0.94 (0.65–1.35) 1.43 (0.74–2.76) 2.66 (1.10–6.42) 0.001
Multivariable
adjusted
1.0 1.01 (0.76–1.35) 0.93 (0.64–1.34) 1.22 (0.62–2.41) 1.67 (0.65–4.29) 0.013
End-stage renal disease
Number of
events
230 25 38 12 11
Demographic
adjusted
1.0 1.36 (0.90–2.05) 3.05 (2.16–4.30) 5.39 (3.00–9.65) 37.33 (20.22–68.94) o0.001
Multivariable
adjusted
1.0 0.89 (0.58–1.35) 2.18 (1.52–3.13) 2.51 (1.34–4.70) 10.62 (4.99–22.60) o0.001
Death
Number of
events
6681 826 551 103 47
Demographic
adjusted
1.0 1.40 (1.30–1.51) 1.41 (1.30–1.54) 1.36 (1.12–1.65) 2.02 (1.52–2.69) o0.001
Multivariable
adjusted
1.0 1.19 (1.10–1.28) 1.23 (1.12–1.34) 1.13 (0.92–1.38) 1.33 (0.98–1.80) o0.001
aNon-recovery was only for those who were defined as AKI stages 1–3, and defined as not being able to become AKI stage 0 (for previous stage I) or not being able to become
AKI stage I (for previous stages 2 or 3). Demographic and multivariable adjustment was performed as described in Table 2.
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defining AKI, and its severity, based on actual creatinine
changes instead of diagnostic codes (which lack sensitivity
and may be prone to secular trends in physician reporting).
In addition, the associations between AKI with adverse
events were robust, despite adjustment for a large number
of clinical measures, including comorbid conditions,
medications, and laboratory measurements. Finally, our
understanding of AKI is further enhanced by our analysis
of recovery from AKI and its impact on the prognostic
implications for each outcome.
Our study also has a number of limitations. First, our
study was retrospective in nature and several pieces of key
information were not obtainable. For example, we could not
conduct the study with measurement of creatinine at regular
time points, we did not have urine output information to
supplement our definition of AKI, and other biomarkers of
kidney damage may be more sensitive in detecting AKI and
preferred for prospective analysis. These factors may have led
to misclassification of AKI in some patients. In addition, we
were unable to perform medical record review to determine
causes of AKI or death in the cohort. Despite these
limitations, serum creatinine is the only marker of kidney
function available for widespread use in the clinical setting,
and thus, our findings may be directly applicable to the care
of hospitalized HIV-infected persons with AKI. Second,
although we accounted for a large number of potential
confounders in our analysis, AKI may still be a marker of
severity of underlying systemic illness, rather than an
independent pathway for adverse events. Third, outpatient
baseline creatinine information was not available for 13% of
patients. Although we tested multiple definitions for baseline
creatinine, AKI may have been misclassified in this subgroup.
Fourth, other studies of long-term outcomes after AKI have
been conducted in the Veterans Affairs (VA) system.12,29
However, our study differs significantly from these reports
which (1) only examined mortality; (2) did not account for
important confounders such as albuminuria; and (3) defined
AKI within an arbitrary time period and thus, did not
include individuals at the time of their first hospitalization.
Fifth, we used the AKI Network criteria to classify changes in
creatinine levels; however, other guidelines define AKI
differently, and none has been validated against a gold
standard of directly measured GFR. Finally, we focused our
analysis on HIV-infected persons receiving care in the VA;
study results may not be applicable to other populations or
health-care systems and women in particular.
Conclusions
AKI is common in HIV-infected persons, affecting 18% of
hospitalized patients. The clinical repercussions of AKI
appear to extend beyond the hospital setting, and may
contribute to excess cardiovascular risk, ESRD, and mortality.
Furthermore, the prognostic associations of AKI with long-
term adverse events may be refined by accounting for
recovery status. These results may provide the foundation for
research aimed at identifying the specific derangements
responsible for adverse event years after AKI and help guide
follow-up care after discharge from the hospital.
METHODS
Data sources
The primary data source was the Department of Veterans Affairs
HIV Clinical Case Registry (CCR).30 The VA HIV CCR contains
demographic, clinical, laboratory, pharmacy, utilization, and death
information from the VA electronic medical record system. To
supplement demographic, clinical, and vital status data, and to
capture health-care utilization outside of the VA system, we further
linked this data source to the VA National Patient Care Database,
Medicare claims, and the VA Beneficiary Identification and Records
Locator Subsystem (BIRLS) Death File.31 We also used the United
States Renal Data System to ascertain prevalent ESRD cases at the
time of cohort entry and new ESRD incidence during follow-up.32
Study population
We identified a national sample of 21,439 HIV-infected US veterans
at the time of their first hospitalization between the years 1986–2006;
hospitalizations for non-medical conditions were not included in
this group. We excluded 1615 patients who died during their
hospitalization, and 1581 who died before the 90th day after
discharge from the hospital. An additional 918 patients who were
already receiving chronic dialysis treatment at the time of admission
were also eliminated from the cohort. The remaining 17,325
individuals were included and entered the study 90 days after their
discharge date.
Definition of AKI
We characterized AKI on the basis of the changes in serum
creatinine levels according to AKI Network (AKIN) criteria.33 AKI
stage 1 was categorized as a crude serum creatinine increase of
0.3mg/dl or greater, or a relative increase between 150 and 200%;
stage 2 was categorized as a relative increase between 200 and 300%;
and stage 3 as either a relative increase greater than 300%, or in
individuals with a serum creatinine level of 4.0mg/dl or greater, a
crude increase of 0.5mg/dl from the baseline. Stages 2 and 3 AKI
were combined in the analysis because of the small number of
individuals in these groups. We also separately categorized
individuals who experienced AKI-requiring dialysis therapy during
their hospitalization, identified using validated diagnostic and
procedural codes.34 The serum creatinine change was defined as
the difference between the peak serum creatinine level during
hospitalization and the most recent outpatient creatinine measure
before hospitalization. In 13% of the study sample, pre-hospitaliza-
tion outpatient creatinine measurements were not available; in these
patients, the first in-patient creatinine level was used as the baseline
measure of kidney function. Among those who experienced AKI,
‘recovery’ was defined as a decrease in serum creatinine below the
threshold level for stage 1 AKI.
Outcomes
The outcomes were time from study entry to: (1) heart failure; (2)
CVD, defined as coronary, cerebrovascular, or peripheral arterial
disease; (3) ESRD, defined as receipt of chronic dialysis therapy
ascertained by the United States Renal Data System; and (4) death.
Cardiovascular outcomes, including heart failure, were defined by
hospitalization for these conditions based on primary discharge
diagnoses and procedural codes in VA and non-VA data sources
using validated algorithms described previously.8,35
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Covariates
Comorbid conditions were identified using a combination of
physician problem lists, ambulatory and hospitalization discharge
diagnoses, procedures, laboratory results, and medication prescrip-
tions in the 2 years period before hospitalization. These included
diabetes, hypertension, dyslipidemia, CVD, lung disease, smoking,
liver disease, and cancer.35–38 We accounted for HIV-related
characteristics such as hepatitis B or C virus co-infection,
antiretroviral therapy, CD4 count, and HIV viral load.39–41 We
also estimated severity of illness based on whether an individual
was hospitalized in the intensive care unit. eGFR at the time of
admission was calculated using the abbreviated Modification of
Diet in Renal Disease formula based on age, sex, race, and
serum creatinine; eGFR was then categorized as X60, 30–59, and
o30ml/min per 1.73m2.42 Albuminuria was defined as urine
dipstick measurements greater than 30mg/dl. We included
a missing indicator category to retain observations in the analysis.
Overall, only 5% of the data was missing; the majority of missing
information was due to HIV viral load and CD4 count in
patients who entered the cohort before when these tests became
widely clinically available. Albuminuria was also missing in 19%
of patients.
Statistical analysis
We compared age-standardized rates of heart failure, CVD, ESRD,
and death by stage of AKI. Rates were calculated using Poisson
regression models, and standardized to the age distribution of the
source population. We used Cox proportional hazards regression
models to determine the adjusted association between AKI with
each outcome independent of demographic characteristics (age, sex,
and race), eGFR category, albuminuria, comorbid conditions,
calendar year, and intensive care unit stay during the first
hospitalization. We built parsimonious models using a backward
stepwise procedure with Po0.05, used as the criterion for inclusion;
age, sex, race, eGFR category, and albuminuria were forced into all
models. For the outcomes of heart failure, CVD, and ESRD,
individuals with events that occurred within the 90 days period after
discharge were excluded from the analysis. Between the date of
discharge and study entry, 550 patients experienced a heart failure or
CVD event and 1616 had ESRD.
The final models for all outcomes included age, sex, race, eGFR
category, albuminuria, CD4 count, hypertension, diabetes, hospita-
lization in the intensive care unit, and calendar year. Models for
heart failure and CVD additionally included history of CVD and
history of heart failure. For mortality, models also included viral
load, lung disease, smoking, and history of CVD. The same models
for each outcome were used for both the initial AKI analyses and the
subsequent models of recovery from AKI. For the outcomes of CVD
and heart failure, respectively, we also stratified by the presence of
CVD, heart failure, and CKD at baseline to determine whether AKI
is associated with de novo cardiovascular events in individuals
without prevalent CKD. We also checked for interactions with
calendar year (antiretroviral treatment era). For the outcomes of
mortality and ESRD, we performed subgroup analyses by age, race,
CKD, CVD, CD4 count, viral load, and intensive care unit stay; in
these analyses, stages of AKI were combined into a dichotomous
variable (AKI versus no AKI) to allow adequate statistical power. We
also further explored the potential effects of prevalent albuminuria
and reduced kidney function on the association between AKI with
mortality by dividing the cohort into four mutually exclusive
categories defined by (1) eGFR460ml/min per 1.73m2 and no
albuminuria, (2) albuminuria only, (3) eGFRo60ml/min per
1.73m2 only, and (4) both reduced GFR and albuminuria.
We conducted a number of sensitivity analyses using alternate
definitions of AKI. When outpatient creatinines were not available,
we explored reclassification of AKI using the nadir in-patient
creatinine to define the baseline measurement. In addition, we
performed a supplementary analysis applying the AKIN 48-h time
criterion for the definition of AKI. An alternative analysis was also
performed using the CKD-EPI equation, instead of the Modification
of Diet in Renal Disease formula, to calculate eGFR.43 We checked
the proportional hazard assumption of the Cox regression models
by comparing plots of log(log(survival)) versus log of survival
time and the Schoenfeld test. All analyses were conducted using
Stata version 11.0 (Stata Corp, College Station, TX, USA).
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